Patient P-02516
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 68 SC-12 recommended — Supportive Compound SC-12
- Day 69 Patient accepted — Started SC-12 in the companion
- Day 75 GI symptom burden −23% vs expected — Supportive Compound SC-12
- Day 81 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 81 Tolerance state changed — Unstable → Improving
- Day 84 ME-01 recommended — Monitoring Escalation ME-01
- Day 85 Patient accepted — Started ME-01 in the companion
- Day 88 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 81.
Primary contributors, last 14 days
- Nutritional resilience-11
- Inflammatory activity+9
- GI instability+5
- Toxicity-3
What helped?
- Supportive Compound SC-12Day 68Result: symptom burden −23%
- Monitoring Escalation ME-01Day 84Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 86% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓65
- WearableResting HR 81 bpm
- Wearable3,930 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.5 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 30/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 63
- Drug metabolism and exposure ↑20
- BloodToxicity index 48
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 30/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 5.3 h
- Steps
- 4,578
- Resting HR
- 77 bpm
Daily log: GI score 59, nutritional resilience 35, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02694 | 62% | S14 | — | — | 56 |
| P-02316 | 61% | S14 | GI-04 | improved | 51 |
| P-02535 | 55% | S14 | SC-12 | improved | 50 |
| P-02628 | 55% | S14 | SC-12 | improved | 47 |
| P-02670 | 54% | S14 | SC-12 | improved | 45 |
| P-02348 | 53% | S14 | GI-04 | improved | 49 |
| P-02401 | 53% | S14 | GI-04 | improved | 49 |
| P-02657 | 51% | S14 | — | — | 42 |
| P-02320 | 49% | S14 | NP-02 | improved | 50 |
| P-02326 | 49% | S18 | NP-02 | improved | 44 |
| P-02253 | 48% | S14 | NP-02 | no change | 41 |
| P-02504 | 48% | S14 | GI-04 | improved | 52 |